2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0194A
    NocII TFA 98%
    NocII TFA is an orphan neuropeptide which stimulates locomotion in mice.
    NocII TFA
  • HY-P0198B
    [D-Arg25]-Neuropeptide Y (human) 98%
    [D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y1 receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.
    [D-Arg25]-Neuropeptide Y (human)
  • HY-P0201F
    Substance P, FAM-labeled 98%
    Substance P, FAM-labeled is a FAM labeled Substance P (HY-P0201).
    Substance P, FAM-labeled
  • HY-P0215A
    Autocamtide-2-related inhibitory peptide, myristoylated TFA 98%
    Autocamtide-2-related inhibitory peptide, myristoylated TFA is the myristoylated Autocamtide-2-related inhibitory peptide. Autocamtide-2-related inhibitory peptide is a highly specific and potent inhibitor of CaMKII with an IC50 of 40 nM.
    Autocamtide-2-related inhibitory peptide, myristoylated TFA
  • HY-P0221A
    PACAP (1-38), human, ovine, rat TFA 98%
    PACAP (1-38), human, ovine, rat TFA is a PAC1 receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC50s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research.
    PACAP (1-38), human, ovine, rat TFA
  • HY-P0244A
    Dermorphin TFA 78331-26-7 98%
    Dermorphin TFA is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain.
    Dermorphin TFA
  • HY-P0249B
    Phe-Met-Arg-Phe, amide acetate 152165-14-5 98%
    Phe-Met-Arg-Phe, amide acetate dose dependently (ED50=23 nM) activates a K+ current in the peptidergic caudodorsal neurons.
    Phe-Met-Arg-Phe, amide acetate
  • HY-P0251A
    Neurotensin(8-13) TFA 2952825-79-3 98%
    Neurotensin (8-13) is an active fragment of Neurotensin. Neurotensin(8-13) TFA results in a decrease in cell-surface NT1 receptors (NTR1) density.
    Neurotensin(8-13) TFA
  • HY-P0252B
    α-MSH free acid 10466-28-1 98%
    α-MSH free acid (α-Melanocyte-Stimulating Hormone free acid) is an MC3R and MC4R agonist with EC50s of 0.16 nM and 5.6 nM, respectively. α-MSH free acid activates cAMP generation at MC3R and MC4R.
    α-MSH free acid
  • HY-P0267A
    Melanotan (MT)-II acetate 1036322-26-5 98%
    Melanotan (MT)-II acetate is a melanocortin receptor agonist that crosses the blood-brain barrier. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction.
    Melanotan (MT)-II acetate
  • HY-P0288A
    [Leu5]-Enkephalin TFA 73563-78-7 98%
    [Leu5]-Enkephalin TFA is a pentapeptide with morphine like properties. [Leu5]-Enkephalin TFA is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.
    [Leu5]-Enkephalin TFA
  • HY-P0307B
    Penetratin-Cys 393511-85-8 98%
    Penetratin-Cys is a cell-penetrating peptide derived from Antennapedia Peptide (HY-P0307) via C-terminal cysteine modification. Penetratin-Cys acts as a cytotoxin and reduces the viability of differentiated neuronal cells. Penetratin-Cys localizes to the perinuclear region and binds to the Golgi apparatus. Penetratin-Cys can be used in research related to neurological disorders.
    Penetratin-Cys
  • HY-P10006
    Leumorphin, human 88846-98-4 98%
    Leumorphin, human is a potent kappa opioid receptor (κ opioid receptor) agonist. Leumorphin, human inhibits the contraction of the myenteric plexus-longitudinal muscle preparation of the guinea pig ileum.
    Leumorphin, human
  • HY-P1001A
    Ac-DEVD-CHO TFA 98%
    Ac-DEVD-CHO TFA is a peptide inhibitor of caspase-3 (Ki=230 pM) and caspase-7. Ac-DEVD-CHO TFA reduces caspase-3 activity and apoptosis induced by Prostaglandin E2 (HY-101952) in rat cortical neurons. Ac-DEVD-CHO TFA is promising for research of neurodegenerative diseases and cancers.
    Ac-DEVD-CHO TFA
  • HY-P10029
    Sakura-6 2490708-79-5 98%
    Sakura-6 is a SERT-nnos interaction promoter that significantly increases the SERT-nnos complex, but reduces the level of SERT on the cell surface. Acute injection of Sakura-6 into the dorsal raphe nucleus (DRN) causes depression-like behavior in mice.
    Sakura-6
  • HY-P10035
    β Amyloid(28-35) human 182945-56-8 98%
    β Amyloid(28-35) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid oligomers are neurotoxic, and β Amyloid(28-35) human can interact with neuronal membranes, regulate secondary structure and neurotoxicity, and cause Alzheimer's disease. β Amyloid(28-35) human has anisotropic effects on the acidic phospholipid DPH, resulting in enhanced internal fluidity of lipid membrane bilayers.
    β Amyloid(28-35) human
  • HY-P10037
    β Amyloid(17-28) human 131580-11-5 98%
    β Amyloid(17-28) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid(17-28) human enhances aggregation of full-length β Amyloid40, producing toxic aggregates in Alzheimer's disease (AD).
    β Amyloid(17-28) human
  • HY-P10039
    β Amyloid (1-16) rat 1123154-43-7 98%
    β-Amyloid (1-16) rat is a β-amyloid peptide (Abeta), a metal-binding domain fragment of amyloid. Three amino acid substitutions in β-Amyloid (1-16) rat that differ from humans render rats and mice less susceptible to AD-like neurodegeneration.
    β Amyloid (1-16) rat
  • HY-P10040
    (Gln22)β-Amyloid (1-40) human 98%
    (Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research.
    (Gln22)β-Amyloid (1-40) human
  • HY-P10077
    GL189 552337-94-7 98%
    GL189 is a β-secretase inhibitor. GL189 has neuroprotective effect, and can be used for research of neurodegenerative diseases.
    GL189
Cat. No. Product Name / Synonyms Application Reactivity